Arkolith/Insider Trading/RPRX/Form 4

Hite Christopher

EVP & Chairman, PartneringRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Jul 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.3M
Net Open-Market Flow
-$7.3M
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Sell(S)97K$56.50$5.5M462K
Jun 30, 2026Sell(S)3K$57.10$146K459K
Jun 30, 2026Sell(S)29K$56.44$1.7M41K
Jun 30, 2026Sell(S)600$57.09$34K40K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001814238-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML